Literature DB >> 18510430

Intracellular delivery of nanoparticles via the HIV-1 tat peptide.

C C Berry1.   

Abstract

Functionalized nanoparticles are heralded as part of the future with regards to targeted cell and nuclear delivery. However, direct intracellular and intranuclear delivery has, until recently, been difficult to achieve owing to the impermeable nature of the plasma and nuclear membranes. During the past 15 years, a range of peptides, termed cell-penetrating peptides (CPPs), which have the ability to translocate into living cells, have been discovered. Thus, in more recent years, the combination of CPPs with nanoparticles, enabling CPP-mediated cell delivery, has opened up many avenues of research. This review discusses the use of various CPPs, focusing on tat peptide, to functionalize nanoparticles and the possible move from the laboratory to the clinic.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18510430     DOI: 10.2217/17435889.3.3.357

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  25 in total

Review 1.  Molecular imaging with SERS-active nanoparticles.

Authors:  Yin Zhang; Hao Hong; Duane V Myklejord; Weibo Cai
Journal:  Small       Date:  2011-09-20       Impact factor: 13.281

Review 2.  Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging.

Authors:  Sonu Bhaskar; Furong Tian; Tobias Stoeger; Wolfgang Kreyling; Jesús M de la Fuente; Valeria Grazú; Paul Borm; Giovani Estrada; Vasilis Ntziachristos; Daniel Razansky
Journal:  Part Fibre Toxicol       Date:  2010-03-03       Impact factor: 9.400

Review 3.  Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.

Authors:  Helen Y Wang; Rong-Fu Wang
Journal:  Adv Immunol       Date:  2012       Impact factor: 3.543

4.  Cell-penetrating HIV1 TAT peptides can generate pores in model membranes.

Authors:  Corina Ciobanasu; Jan Peter Siebrasse; Ulrich Kubitscheck
Journal:  Biophys J       Date:  2010-07-07       Impact factor: 4.033

Review 5.  Targeted hyperthermia using metal nanoparticles.

Authors:  Paul Cherukuri; Evan S Glazer; Steven A Curley
Journal:  Adv Drug Deliv Rev       Date:  2009-11-10       Impact factor: 15.470

6.  Selective inhibition of human brain tumor cells through multifunctional quantum-dot-based siRNA delivery.

Authors:  Jongjin Jung; Aniruddh Solanki; Kevin A Memoli; Ken-ichiro Kamei; Hiyun Kim; Michael A Drahl; Lawrence J Williams; Hsian-Rong Tseng; KiBum Lee
Journal:  Angew Chem Int Ed Engl       Date:  2010       Impact factor: 15.336

7.  The potential of nanomedicine therapies to treat neovascular disease in the retina.

Authors:  Krysten M Farjo; Jian-Xing Ma
Journal:  J Angiogenes Res       Date:  2010-10-08

8.  Polydopamine-based surface modification for the development of peritumorally activatable nanoparticles.

Authors:  Emily Gullotti; Joonyoung Park; Yoon Yeo
Journal:  Pharm Res       Date:  2013-04-23       Impact factor: 4.200

Review 9.  HIV-1 neuroimmunity in the era of antiretroviral therapy.

Authors:  Stephanie D Kraft-Terry; Andrew R Stothert; Shilpa Buch; Howard E Gendelman
Journal:  Neurobiol Dis       Date:  2010-01-04       Impact factor: 5.996

10.  Beyond the imaging: limitations of cellular uptake study in the evaluation of nanoparticles.

Authors:  Emily Gullotti; Yoon Yeo
Journal:  J Control Release       Date:  2012-05-05       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.